长期服用奥氮平精神分裂症患者稳定期认知功能与代谢综合征的关系

被引：27

作者：

高慧 ^{[1
]}

姚培芬 ^{[2
]}

盛嘉玲 ^{[1
]}

戴晶璟 ^{[1
]}

王卫平 ^{[3
]}

唐伟 ^{[4
]}

张晨 ^{[2
]}

机构：

[1] 上海市民政第一精神卫生中心

[2] 上海交通大学医学院附属精神卫生中心

[3] 浙江省金华第二医院

[4] 温州康宁医院

来源：

临床精神医学杂志 | 2017年 / 27卷 / 05期

关键词：

奥氮平; 认知功能; 精神分裂症; 代谢综合征; 血糖;

D O I：

暂无

中图分类号：

R589 [代谢病]; R749.3 [精神分裂症];

学科分类号：

100201 [内科学]; 100204 [神经病学];

摘要：

目的:探讨伴或不伴代谢综合征患者认知功能的差异及其影响因素。方法:采用《美国国家胆固醇教育项目成人治疗组第3次指南》(NCEP-ATPⅢ)诊断标准,将216例长期单药使用奥氮平治疗的精神分裂症患者分为MS组和非MS组,采用重复性神经心理状态测验(RBANS)评估认知功能。结果:MS组与非MS组间奥氮平使用时间和剂量差异有统计学意义(P<0.01)。生化指标在两组间比较结果显示MS组体质量指数(BMI)、腰围、空腹血糖(GLU)、三酰甘油(TG)、血压水平均显著高于非MS组(P<0.05或P<0.01),而MS组高密度脂蛋白(HDL)水平显著低于非MS组(P<0.01)。多因素方差分析显示MS组RBANS测试中即刻记忆、注意、延迟记忆及总分低于非MS组(P<0.01)。多元回归分析结果显示RBANS总分与GLU水平呈负相关(t=-2.57,P=0.01)。结论:伴MS精神分裂症患者相比不伴MS患者认知功能更差,高血糖可能参与了认知缺损的发生机制并提示了缺损严重程度。

引用

收藏

页码：293 / 296

页数：4

相关论文

共 9 条

[1]

Glutamate receptor 1 phosphorylation at serine 845 contributes to the therapeutic effect of olanzapine on schizophrenia-like cognitive impairments [J].

Zhang, Chen ;

Fang, Yiru ;

Xu, Lin .

SCHIZOPHRENIA RESEARCH, 2014, 159 (2-3) :376-384

[2]

Metabolic syndrome in patients taking clozapine: prevalence and influence of catechol-O-methyltransferase genotype [J].

Zhang, Yi ;

Chen, Meijuan ;

Chen, Jun ;

Wu, Zhiguo ;

Yu, Shunying ;

Fang, Yiru ;

Zhang, Chen .

PSYCHOPHARMACOLOGY, 2014, 231 (10) :2211-2218

[3]

Metabolic Syndrome and Its Factors Affect Cognitive Function in Chronic Schizophrenia Complicated by Metabolic Syndrome [J].

Li, Chenhu ;

Zhan, Guilai ;

Rao, Shunzeng ;

Zhang, Hong .

JOURNAL OF NERVOUS AND MENTAL DISEASE, 2014, 202 (04) :313-318

[4]

Second Generation Antipsychotic-Induced Type 2 Diabetes: A Role for the Muscarinic M3 Receptor [J].

Weston-Green, Katrina ;

Huang, Xu-Feng ;

Deng, Chao .

CNS DRUGS, 2013, 27 (12) :1069-1080

[5]

A randomized controlled trial of olanzapine improving memory deficits in Han Chinese patients with first-episode schizophrenia [J].

Wang, Chang-Hong ;

Li, Yan ;

Yang, Jun ;

Su, Lin-Yan ;

Geng, Yao-Guo ;

Li, Hao ;

Wang, Ji-Kang ;

Mu, Jun-Lin .

SCHIZOPHRENIA RESEARCH, 2013, 144 (1-3) :129-135

[6]

Relationship between metabolic syndrome and cognition in patients with schizophrenia [J].

Lindenmayer, Jean Pierre ;

Khan, Anzalee ;

Kaushik, Saurabh ;

Thanju, Amod ;

Praveen, Rajalakshmi ;

Hoffman, Lisa ;

Cherath, Lata ;

Valdez, Gladys ;

Wance, Deborah .

SCHIZOPHRENIA RESEARCH, 2012, 142 (1-3) :171-176

[7]

Cognitive Effects of Atypical Antipsychotic Medications in Patients With Alzheimer's Disease: Outcomes From CATIE-AD [J].

Vigen, Cheryl L. P. ;

Mack, Wendy J. ;

Keefe, Richard S. E. ;

Sano, Mary ;

Sultzer, David L. ;

Stroup, T. Scott ;

Dagerman, Karen S. ;

Hsiao, John K. ;

Lebowitz, Barry D. ;

Lyketsos, Constantine G. ;

Tariot, Pierre N. ;

Zheng, Ling ;

Schneider, Lon S. .

AMERICAN JOURNAL OF PSYCHIATRY, 2011, 168 (08) :831-839

[8]

Effects of olanzapine, sertindole and clozapine on learning and memory in the Morris water maze test in naive and MK-801-treated mice [J].

Mutlu, Oguz ;

Ulak, Guner ;

Celikyurt, Ipek Komsuoglu ;

Akar, Furuzan Yildiz ;

Erden, Faruk .

PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR, 2011, 98 (03) :398-404

[9]

Prevalence of the metabolic syndrome in patients with schizophrenia: Baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Schizophrenia Trial and comparison with national estimates from NHANES III [J].

McEvoy, JP ;

Meyer, JM ;

Goff, DC ;

Nasrallah, HA ;

Davis, SA ;

Sullivan, L ;

Meltzer, HY ;

Hsiao, J ;

Stroup, TS ;

Lieberman, JA .

SCHIZOPHRENIA RESEARCH, 2005, 80 (01) :19-32